Format

Send to

Choose Destination
Oncotarget. 2017 May 23;8(53):91703-91710. doi: 10.18632/oncotarget.18114. eCollection 2017 Oct 31.

Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma.

Author information

1
Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy.
2
Department of Cellular Biotechnologies and Hematology, Hematology, Sapienza University, Rome, Italy.
3
Department of Hematology, University and Hospital Careggi, Firenze, Italy.
4
Department of Hematology, Azienda Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy.
5
Department of Hematology, Ospedali Riuniti di Ancona, Ancona, Italy.
6
Hematology Unit, Ospedale Papardo, Messina, Italy.
7
Hematology Unit, Santa Maria delle Croci Hospital, Ravenna, Italy.
8
Division of Hematology, Niguarda Hospital, Milan, Italy.
9
Division of Hematology, AOU, Catania, Italy.
10
European Institute of Oncology, Milano, Italy.
11
Hematology, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Torino, Italy.
12
Oncology and Hematology, Humanitas Cancer Center, Rozzano, Italy.
13
Institute of Hematology, Catholic University, Rome, Italy.
14
Hematology Section, St. Anna University Hospital, Cona, Ferrara, Italy.
15
Scientific Direction, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, Pz, Italy.
16
Ospedale Moscati, Department of Hematology-Oncology, Taranto, Italy.
17
Department of Hematology, Ciaccio-Pugliese Hospital, Catanzaro, Italy.
18
Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, Milan, Italy.
19
Hematology Unit, Arcispedale Santa Maria Nuova, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy.
20
Hematology Unit, Policlinico di Bari, Bari, Italy.
21
Hematology, Ospedale di Circolo, Fondazione Macchi, Varese, Italy.
22
Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Napoli, Italy.
23
Department of Hematology, Hospital Papa Giovanni XXIII, Bergamo, Italy.
24
Division of Hematology, Guglielmo da Saliceto Hospital, Piacenza, Italy.
25
Hematology Unit, Infermi Hospital Rimini, Rimini, Italy.
26
Hematology, Ospedale Perugia, Perugia, Italy.
27
Hematology-Oncology and Stem Cell Transplantation Unit, National Cancer Institute, Fondazione Pascale, IRCCS, Napoli, Italy.
28
Division of Hematology, Ospedale G. Panico, Tricase, Lecce, Italy.
29
Hematology Unit, Ca' Foncello Hospital, Treviso, Italy.
30
Sant'Andrea Hospital, Sapienza University, Rome, Italy.
31
Department of Hematology, DISM, Azienda Sanitaria Universitaria Integrata, Udine, Italy.
32
Department of Medicine, Hematology and Clinical Immunology Unit, University of Padua, Padua, Italy.
33
Onco-Hematology Unit, Fondazione Ca' Granda IRCCS Ospedale Maggiore Policlinico, Milan, Italy.
34
Hematology, IRCCS Policlinico San Matteo, Pavia, Italy.
35
Hematology, AOU Federico II Napoli, Napoli, Italy.
36
Hematology, San Bortolo Hospital, Vicenza, Italy.
37
Division of Medical Oncology A, National Cancer Institute, Aviano, Italy.
38
Division of Hematology 1, IRCCS A.O.U. San Martino IST, Genova, Italy.

Abstract

A large Italian multicenter observational retrospective study was conducted on the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin's lymphoma (HL) to check if clinical trial results are confirmed even in a real life context. 234 CD30+ HL patients were enrolled. Best response was observed after a median of 4 cycles in 140 patients (59.8%): 74 (31.6%) patients obtained a complete response (CR) and 66 (28.2%) achieved a partial response (PR); overall response rate at the end of the treatment was 48.3% (62 CR and 51 PR). The best response rate was higher in the elderly subset: 14 (50%) CR and 5 (17.8%) PR. Disease free survival was 26.3% at 3 years and progression free survival 31.9% at 4.5 years. Duration of response did not differ for who achieved at least PR and then either did or did not undergo consolidative transplant. Overall, the treatment was well tolerated and no death has been linked to BV-induced toxicity. Our report confirms activity in elderly patients, duration of response unrelated to the consolidation with transplant procedure, the relevance of the CR status at first restaging, and the role of BV as a bridge to transplant for chemorefractory patients.

KEYWORDS:

Hodgkin’s lymphoma; brentuximab vedotin; long-term response; real life; stem cell transplantation

Conflict of interest statement

CONFLICTS OF INTEREST No potential conflicts of interest were disclosed.

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center